FTC Wants More Info On Genzyme/Ilex Merger; Firms See No Delay In Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The inquiry is spurred by independent studies on Ilex’ leukemia agent Campath for transplant treatment, which could overlap with Genzyme’s Thymoglobulin.